裸盖菇素辅助治疗难治性抑郁症的随机对照可行性试验
在英格兰一家NHS机构开展双臂双盲安慰剂对照可行性试验,60例难治性重性抑郁障碍患者按1:1随机接受单次25 mg裸盖菇素或安慰剂并辅以心理支持。第3周MADRS组间校正差值-10.41(95%CI -14.86至-5.95),支持后续确证性试验。
要点
- 单次25 mg裸盖菇素辅以心理支持在第3周和第6周均优于安慰剂。
- 第3周MADRS校正组间差值-10.41(95%CI -14.86至-5.95;Cohen's d=-1.70)。
- 研究为可行性试验,主要结局为招募、保留和MADRS方差估计。
核心结论
- 单次25 mg裸盖菇素辅以心理支持在难治性重性抑郁障碍中显示出优于安慰剂的MADRS改善,支持开展未来确证性试验。
研究设计与样本
- 在英格兰一家National Health Service(NHS)机构开展的两臂、双盲、随机、安慰剂对照可行性试验,随访6周。
- 60例符合DSM-5重性抑郁障碍标准且对≥2种抗抑郁治疗或≥1种抗抑郁药加≥1种心理治疗应答不足的参与者按1:1随机分组。
- 参与者接受25 mg裸盖菇素或安慰剂,并配合准备、给药支持和整合环节。
- 主要结局为招募、保留和Montgomery-Åsberg Depression Rating Scale(MADRS)方差估计,采用意向性治疗人群的多层回归分析。
主要发现
- 60例参与者按1:1随机,按年龄、性别和既往裸盖菇素暴露平衡,59/60例在所有随访访视完成MADRS。
- 第3周MADRS校正组间差值为-10.41(95%CI -14.86至-5.95;Cohen's d=-1.70),有利于裸盖菇素组。
- 该差异在第6周持续存在。
- 安慰剂组和裸盖菇素组分别发生123例和164例非严重不良事件。
局限性
- 本研究为可行性试验,主要目的是评估招募、保留和MADRS方差估计,而非确证疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health Service (NHS) site in England. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for major depressive disorder and had an inadequate response to ≥2 antidepressant treatments or ≥1 antidepressant plus ≥1 psychotherapy. Participants received 25-mg psilocybin or placebo with preparation, dosing support and integration. Primary outcomes were recruitment, retention and estimation of the Montgomery-Åsberg Depression Rating Scale (MADRS) variance. A multilevel regression analysis with an intention-to-treat population was used. Sixty participants were randomized (1:1), balanced by age, sex and prior psilocybin exposure, and 59 of 60 participants completed the MADRS at all follow-up visits. The adjusted between-group difference at week 3 on the MADRS was -10.41 (95% confidence interval: -14.86 to -5.95; Cohen's d = -1.70), favoring psilocybin, which was sustained at week 6. In total, 123 and 164 nonserious adverse events occurred in the placebo and psilocybin arms, respectively. Findings support a future confirmatory trial. EudraCT no.: 2018-003573-97 .
引用
- Rucker JJ, Mantingh T, Kerr-Gaffney J, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nat Med. 2026. PMID: 42562964. doi:10.1038/s41591-026-04541-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。